Lenalidomide

證據等級: L5

預測適應症: 10 個

Lenalidomide: From Multiple Myeloma / del(5q) MDS to Myeloid Leukemia

One-Sentence Summary

Lenalidomide is an oral immunomodulatory drug (IMiD) originally approved in multiple countries for multiple myeloma and transfusion-dependent anemia due to low-risk myelodysplastic syndrome (MDS) with del(5q) cytogenetic abnormality — though it carries no Taiwan regulatory registration at this time. The TxGNN model predicts it may be effective for Myeloid Leukemia (encompassing AML and the broader MDS spectrum beyond del(5q)), with multiple completed Phase 2/3 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Multiple Myeloma; del(5q) MDS (global approvals — not registered in Taiwan)
Predicted New Indication	Myeloid Leukemia
TxGNN Prediction Score	99.49%
Evidence Level	L1
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Lenalidomide exerts its anti-cancer activity primarily through the cereblon (CRBN)–CRL4A E3 ubiquitin ligase complex. By binding CRBN, lenalidomide redirects the ligase to ubiquitinate and proteasomally degrade key transcription factors — most notably IKZF1 (Ikaros) and CK1α (encoded by CSNK1A1 at chromosomal locus 5q31.2). The resulting loss of these proteins drives selective apoptosis in malignant hematopoietic cells while sparing most normal progenitors. In parallel, lenalidomide enhances NK cell–mediated cytotoxicity, suppresses regulatory T cells (Tregs), and inhibits pro-tumorigenic cytokines including TNF-α and VEGF, creating a multi-pronged anti-tumor immune environment.

The mechanistic connection to myeloid leukemia is most directly established in the del(5q) AML subtype. In cells carrying a 5q31.2 deletion, haploinsufficiency of CSNK1A1 leaves only one functional CK1α allele. Lenalidomide-driven CK1α degradation pushes these cells below a critical threshold, triggering p53-dependent selective apoptosis — while normal cells with two intact alleles produce sufficient residual CK1α and are relatively spared. This biology directly underpins lenalidomide’s established efficacy in del(5q) MDS (globally approved) and provides a biologically grounded rationale for extension into del(5q) AML.

Beyond the del(5q) subtype, the close biological relationship between MDS and AML — both arising from clonal hematopoietic stem cell disorders, with MDS frequently progressing to AML — supports applying lenalidomide across the broader myeloid leukemia spectrum. Multiple clinical programs have combined lenalidomide with hypomethylating agents (azacitidine) and conventional chemotherapy (MEC: mitoxantrone, etoposide, cytarabine), or employed it as post-remission maintenance, demonstrating active clinical investigation in AML across multiple lines of therapy and patient age groups.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00179621	Phase 3	Completed	205	Multicenter randomized double-blind placebo-controlled 3-arm study comparing lenalidomide 10 mg vs 5 mg vs placebo in transfusion-dependent low/intermediate-1 risk MDS with del(5q); highest-quality evidence in myeloid disease
NCT03118466	Phase 2	Completed	41	MEC (mitoxantrone, etoposide, cytarabine) + lenalidomide in relapsed/refractory AML adults; provides direct efficacy and safety data for lenalidomide in AML combination therapy
NCT01358734	Phase 2	Completed	88	3-arm randomized trial of lenalidomide alone, sequential azacitidine + lenalidomide, or azacitidine alone in elderly (≥65 y) newly diagnosed AML
NCT01743859	Phase 2	Completed	37	Sequential azacitidine and lenalidomide in relapsed/refractory AML; primary endpoint CR/CRi rate
NCT02538965	Phase 2	Completed	17	Single-agent lenalidomide in pediatric relapsed/refractory AML (≥2nd relapse or refractory to ≥2 induction attempts); assessed morphological complete response within first 4 cycles
NCT04490707	Phase 3	Unknown	60	Azacitidine + lenalidomide as MRD-monitored maintenance in elderly/unfit AML patients; MRD-guided strategy based on Chinese registry data
NCT02126553	Phase 2	Completed	29	Lenalidomide maintenance in high-risk AML in first remission; investigated immune mechanism of disease-free survival benefit
NCT01522976	Phase 2	Active, Not Recruiting	282	Randomized Phase II/III: azacitidine ± lenalidomide vs ± vorinostat in higher-risk MDS and CMML; large comparative dataset with long follow-up
NCT01442714	Phase 2	Terminated	33	Azacitidine + lenalidomide in elderly previously treated AML; early termination limits conclusions but combination safety data remain informative
NCT00831766	Phase 1/2	Completed	51	Sequential idarubicin + cytarabine followed by lenalidomide in MDS (RAEB-2) or untreated AML; evaluated safety, response rates, and response duration

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31221030	2019	Systematic Review & Meta-analysis	Hematology	Pooled analysis of azacitidine + lenalidomide in AML, high-risk MDS, and CMML; evaluated overall response rate, CR rate, and adverse event profile
30271212	2018	Systematic Review & Meta-analysis	Cancer Manag Res	Comprehensive review of lenalidomide efficacy and safety specifically in AML; addressed controversy over whether lenalidomide significantly improves response and OS
39881283	2025	Mechanistic Study	Cell Mol Biol Lett	Identified KDM5C histone demethylase as a CRBN stabilizer; KDM5C enhances AML cell sensitivity to lenalidomide by maintaining CRBN protein levels — clarifies resistance mechanism
37259567	2023	Prospective Phase 2 (Azalena Trial)	Haematologica	Azacitidine + lenalidomide + donor lymphocyte infusions as first salvage for post-transplant relapse of AML, MDS, and CMML; 50 patients enrolled, prospective design
37288607	2023	Review	Am J Hematol	MDS 2023 update on diagnosis, risk stratification, and management; covers lenalidomide’s established role and current guideline positioning
23644421	2013	Review / Trial Report	Leukemia	Critical appraisal of azacitidine + lenalidomide combination rationale in advanced MDS/AML; discusses epigenetic and immunological synergism
35512188	2022	Retrospective Cohort	Blood	⚠️ Safety Warning: Lenalidomide exposure selectively promotes TP53-mutated therapy-related myeloid neoplasms through clonal positive selection pressure (n=416 t-MN patients)
23316859	2013	Review	Expert Opin Investig Drugs	Comprehensive review of lenalidomide as a novel AML treatment; summarizes clinical trial results and mechanistic rationale across AML subtypes
34471239	2021	Phase 1 Trial	Bone Marrow Transplant	Lenalidomide maintenance post-allogeneic transplant in unfavorable-risk AML and high-risk MDS; dose-escalation (5–15 mg) safety study, n=16
37435080	2023	Prospective Study	Front Immunol	Azacitidine + low-dose lenalidomide as post-allo-HSCT relapse prophylaxis in AML (ChiCTR2200061803); reports efficacy and tolerability with MRD guidance

Cytotoxicity

Item	Content
Cytotoxicity Classification	Immunomodulatory agent (IMiD) — not a conventional cytotoxic; anti-leukemic activity via CRBN-mediated degradation of IKZF1 and CK1α (targeted mechanism)
Myelosuppression Risk	High — thrombocytopenia and neutropenia are the primary dose-limiting toxicities observed across del(5q) MDS and AML clinical trials
Emetogenicity Classification	Low
Monitoring Items	CBC with differential (weekly for first 8 weeks, then monthly); serum creatinine / eGFR — dose adjustment required when CrCl < 60 mL/min (lenalidomide is renally excreted); liver function tests
Handling Protection	Standard oral oncology precautions; teratogenic risk mandatory prevention program required (REMS in the US; Pregnancy Prevention Programme in EU/EMA) — thalidomide structural analogue with confirmed Category X teratogenicity

Safety Considerations

No Taiwan regulatory warnings, contraindications, or drug-drug interaction data are available in this Evidence Pack. Two critical safety signals are identified from the published literature:

Therapy-related secondary malignancy: Retrospective analysis of 416 therapy-related myeloid neoplasm patients (PMID 35512188) found that lenalidomide exposure selectively promotes outgrowth of TP53-mutated clones through positive selection pressure, increasing the risk of therapy-related myeloid neoplasms. This finding must be proactively disclosed in informed consent for any off-label or investigational use.
Secondary B-cell acute lymphoblastic leukemia (B-ALL): Multiple case series and cohort studies report secondary B-ALL following lenalidomide-containing regimens, particularly in the setting of autologous stem cell transplant with lenalidomide maintenance (PMID 32880627, PMID 33512465). Active longitudinal surveillance for lineage switch is warranted.

Please refer to the current SmPC and/or US Prescribing Information for complete, up-to-date safety details.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence base for lenalidomide in myeloid leukemia meets L1 criteria, anchored by two completed Phase 3 RCTs in myeloid disease (NCT00179621, n=205; NCT01029262, n=239), multiple completed Phase 2 trials directly in AML (including NCT03118466 and NCT01358734), and a systematic review with meta-analysis (PMID 31221030). The mechanistic rationale — CRBN-mediated CK1α degradation with haploinsufficiency amplification in del(5q) cells — is among the most precisely characterized in drug repurposing. However, the absence of Taiwan regulatory data, the documented secondary malignancy risk (TP53 clonal selection; secondary B-ALL), and the lack of formal MOA documentation in the Evidence Pack necessitate structured guardrails before clinical application.

To proceed, the following is needed:

Obtain TFDA prescribing information or SmPC: key warnings, contraindications, and drug-drug interaction profile (resolve Data Gap DG001)
Retrieve DrugBank MOA documentation to formally characterize the mechanism for regulatory submissions (resolve Data Gap DG002)
Define patient selection criteria by cytogenetic subtype (del(5q) vs. non-del(5q)) to optimize the therapeutic index
Establish a secondary malignancy surveillance protocol: periodic molecular testing for TP53 clonal evolution and B-ALL lineage monitoring
Clarify the regulatory pathway for compassionate use, named-patient access, or clinical trial enrollment in Taiwan (given current non-marketing status)
Implement a mandatory pregnancy prevention program before any clinical use, consistent with global REMS/PPP requirements
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.